SAVIMS

SAVIMS logo white
Menu

February 2021

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Efficacy and Safety of Janssen’s Ad26.COV2.S Vaccine for COVID-19

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: FDA. (2021). Vaccines and related biological products advisory committee meeting: February 26, 2021. Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. FDA Briefing Document. Summary: The FDA briefing document details the Emergency Use Authorization (EUA) request submitted by Janssen Biotech for the Ad26.COV2.S vaccine aimed at preventing COVID-19. This single-dose adenovirus vector vaccine demonstrated […]

COVID-19, Ivermectin, News, Other scientific evidence, Treatment, Viral illnesses

BIRD Recommendation on Ivermectin for Covid-19

| | COVID-19, Ivermectin, News, Other scientific evidence, Treatment, Viral illnesses

Reference: British Ivermectin Recommendation Development. (2021). The BIRD recommendation on the use of ivermectin for Covid-19: Executive summary. Proceedings and conclusions of the British Ivermectin Recommendation Development meeting. Summary: The British Ivermectin Recommendation Development (BIRD) meeting, held on 20th February 2021 in Bath, aimed to evaluate ivermectin’s efficacy in treating and preventing Covid-19, especially in

Scroll to Top